Clinical observation of vitreous surgery combined with intravitreal injection of bevacizumab to treat proliferative diabetic retinopathy

Abstract

Objective To observe the effect of vitreous surgery combined with intravitreal injection of bevacizumab to treat proliferative diabetic retinopathy (PDR).Methods A retrospective analysis,comparative study.From September 2012 to September 2013 57 cases (59 eyes) were diagnosed PDR (Ⅳ～Ⅵ) in the study.All the patients were randomly divided into two groups.The first group underwent combined treatment (PPV+IVB) including firstly routine vitrectomy and intravitreal injection of bevacizumab (1.5mg) postoperatively.The second group underwent only vitrectomy (PPV) which was pure vitreous operation.After operation,visual acuity,intraocular pressure and complications such as vitreous hemorrhage were observed in both groups.The follow-up time was longer than 3 months (average 4.3 months).Finally the data was collected and chi square test was used for statistical analysis.Results Among them,28 patients (28 eyes) underwent vitrectomy combined with intravitreal injection of bevacizumab and 29 cases (31 eyes) underwent only vitreous operation.Comparing visual acuity increased cases in the two groups,there were 23 eyes in PPV+IVB group,the proportion were 82.1％ (23/28); there were 18 eyes in PPV group,the proportion was 58.1％ (18/ 31).After statistical analysis,x2-4.023,P 0.045,there was a statistically significant difference; Comparing recurrent vitreous hemorrhage after operation,There were 3 eyes in PPV+IVB group,the proportion was 10.7％ (3/28); There were 11 eyes in PPV group 10 eyes,the proportion was 35.5％ (11/31).After statistical analysis,between the two groups,x2=.987,P 0.026,there was a statistically significant difference.Conclusions Vitrectomy combined with intravitreal injection of bevacizumab for treating PDR is helpful to the improvement of visual acuity after surgery,the prevention of postoperative complications such as vitreous recurrent hemorrhage. Key words: Bevacizumab; Proliferative diabetic retinopathy; Vitreous surgery